Showing 3111-3120 of 5646 results for "".
- Researchers Define Keys to Recognizing Ocular Rosaceahttps://modernod.com/news/researchers-define-keys-to-recognizing-ocular-rosacea/2480589/A pair of new studies help establish the relative prevalence of signs and symptoms of the eyes of rosacea patients (ocular rosacea), as well as the importance of
- Modular Super-Enhancer Controls Retinal Developmenthttps://modernod.com/news/modular-super-enhancer-controls-retinal-development/2480571/Scientists at St. Jude Children’s Research Hospital identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer. Enhancers are regions of DNA that do not
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-36-months-in-phase-2b-study/2480567/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 36-month analysis of the phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. <
- Aramis Biosciences Receives FDA Clearance to Proceed with Phase 2 Trail of A197, a Novel Immunomodulatory Agent for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-receives-fda-clearance-to-proceed-with-phase-2-trail-of-a197-a-novel-immunomodulatory-agent-for-the-treatment-of-dry-eye-disease/2480558/Aramis Biosciences announced that the FDA has cleared the investigational new drug (IND) application for A197, enabling the company to proceed with a phase 2 proof of concept clinical trial. “We are pleased that FDA has cleared A197 to move into phase 2 clinica
- Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division with Acquisition of Warden Biohttps://modernod.com/news/kriya-expands-gene-therapy-pipeline-and-establishes-its-rare-disease-therapeutic-area-division-with-the-acquisition-of-warden-bio/2480550/Gene therapy company Kriya Therapeutics announced that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs.</
- Prevent Blindness Issues Call for Nominations for 2022 National Awardshttps://modernod.com/news/prevent-blindness-issues-call-for-nominations-for-2022-national-awards/2480547/
- Harrow Health Acquires US Commercial Rights to Four Branded Eye Drops from Novartishttps://modernod.com/news/harrow-health-imprimisrx-acquires-us-commercial-rights-to-four-branded-eye-drops-from-novartis/2480527/Harrow Health, the parent company of ImprimisRx, announced its has acquired the exclusive US commercialization rights of four FDA-approved ophthalmic medicines—Iopidine 1% and 0.5% (apraclonidine hydroc
- ImprimisRx to Assume Full Responsibility for US Sales and Marketing Activities for Dexycuhttps://modernod.com/news/imprimisrx-to-assume-full-responsibility-for-us-sales-and-marketing-activities-for-dexycu/2480499/EyePoint Pharmaceut
- Ophthalmic Sciences Unveils AI Contactless Device for Measuring IOPhttps://modernod.com/news/ophthalmic-sciences-unveils-ai-contactless-device-for-measuring-iop/2480487/
- IOLCon Designed to Map Out the Road for Reliable IOL Calculationhttps://modernod.com/news/iolcon-is-mapping-out-the-road-for-reliable-iol-calculation/2480474/Internet database IOLCon announced updates to its website,